BRPI1011325A2 - composições e métodos para o tratamento de inflamação - Google Patents

composições e métodos para o tratamento de inflamação

Info

Publication number: BRPI1011325A2
Authority: BR; Brazil
Prior art keywords: compositions; methods; treating inflammation; inflammation; treating
Prior art date: 2009-04-13

Application number

BRPI1011325A

Other languages

English (en)

Inventor

C Eric Schwartz

Per Gjorstrup

Original Assignee

C T Resolve Sàrl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-13

Filing date

2010-04-13

Publication date

2016-03-15

2010-04-13 Application filed by C T Resolve Sàrl filed Critical C T Resolve Sàrl

2016-03-15 Publication of BRPI1011325A2 publication Critical patent/BRPI1011325A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Obesity (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)

BRPI1011325A 2009-04-13 2010-04-13 composições e métodos para o tratamento de inflamação BRPI1011325A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16873909P	2009-04-13	2009-04-13
US17480609P	2009-05-01	2009-05-01
PCT/US2010/030813 WO2010120719A1 (en)	2009-04-13	2010-04-13	Compositions and methods for the treatment of inflammation

Publications (1)

Publication Number	Publication Date
BRPI1011325A2 true BRPI1011325A2 (pt)	2016-03-15

Family

ID=42982804

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1011325A BRPI1011325A2 (pt)	2009-04-13	2010-04-13	composições e métodos para o tratamento de inflamação

Country Status (15)

Country	Link
US (2)	US8673881B2 (pt)
EP (1)	EP2419399B1 (pt)
JP (1)	JP5785537B2 (pt)
CN (1)	CN104203901A (pt)
AU (1)	AU2010236663B2 (pt)
BR (1)	BRPI1011325A2 (pt)
CA (1)	CA2758586A1 (pt)
CL (1)	CL2011002548A1 (pt)
ES (1)	ES2576086T3 (pt)
IL (1)	IL215592A (pt)
MX (1)	MX2011010827A (pt)
NZ (1)	NZ596228A (pt)
RU (1)	RU2543720C2 (pt)
TW (1)	TW201039815A (pt)
WO (1)	WO2010120719A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7582785B2 (en) *	2002-04-01	2009-09-01	University Of Southern California	Trihydroxy polyunsaturated eicosanoid derivatives
US8900626B2 (en) *	2011-06-20	2014-12-02	Senju Usa, Inc.	Transdermal drug delivery system and method of using the same
RU2497498C2 (ru) *	2012-02-14	2013-11-10	Константин Николаевич Руссков	Фармацевтическая композиция для профилактики пролиферативной клеточной реакции "митомицин-о"
ES2811799T3 (es)	2012-08-22	2021-03-15	Messina David Rafael Rosenberg	Utilización de estatinas para la enfermedad periodontal y regeneración ósea
US20150246061A1 (en) *	2012-10-19	2015-09-03	Celus Pharmaceuticals, Inc.	Vitamin d analogues for the treatment of a neurological disorder
US11058659B2 (en)	2013-02-22	2021-07-13	University Of Southern California	Methods and compositions for the treatment of ophalmic diseases and disorders
WO2016028800A1 (en) *	2014-08-20	2016-02-25	A.T. Resolve Sarl	Treatment of corneal haze
JP2018509412A (ja)	2015-03-10	2018-04-05	イーエルシーマネージメントエルエルシー	炎症を収束させるよう皮膚を処置するための方法および組成物ならびに炎症収束経路を刺激する活性物質のスクリーニング
CN105287480B (zh) *	2015-10-28	2019-01-11	西安医学院第一附属医院	Resolvin D1作为抗癫痫药物的应用
US12161688B2 (en)	2016-06-30	2024-12-10	Mapi Pharma Ltd	Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
WO2018211486A1 (en) *	2017-05-15	2018-11-22	Stem Cell Medicine Ltd.	Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
CN107445821A (zh) *	2017-08-11	2017-12-08	上海中医药大学	聚炔酸类衍生物
IL281166B2 (en)	2018-09-04	2025-08-01	Minerva Neurosciences Inc	Methods of using a phenoxypropylamine compound to treat pain
CN114269901B (zh) *	2019-08-27	2024-12-20	赛琳技术有限公司	用于治疗肢体缺血的激活的间充质干细胞
AU2020402031A1 (en) *	2019-12-09	2022-06-30	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Biomolecule for treatment of corneal pathologies
CN110988180A (zh) *	2019-12-19	2020-04-10	山东达因海洋生物制药股份有限公司	一种基于杂质谱的埃索美拉唑镁的有关物质分析方法
US20250381161A1 (en) *	2022-06-21	2025-12-18	Anida Pharma Inc.	Compositions and methods for treating hearing and ocular disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4172896A (en)	1978-06-05	1979-10-30	Dainippon Pharmaceutical Co., Ltd.	Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4444784A (en)	1980-08-05	1984-04-24	Merck & Co., Inc.	Antihypercholesterolemic compounds
MX7065E (es)	1980-06-06	1987-04-10	Sankyo Co	Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en)	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
US4681893A (en)	1986-05-30	1987-07-21	Warner-Lambert Company	Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
JP2648897B2 (ja)	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
GB9217295D0 (en)	1992-08-14	1992-09-30	Wellcome Found	Controlled released tablets
US5358970A (en)	1993-08-12	1994-10-25	Burroughs Wellcome Co.	Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en)	1993-07-30	1993-09-15	Wellcome Found	Stabilized pharmaceutical
US5541231A (en)	1993-07-30	1996-07-30	Glaxo Wellcome Inc.	Stabilized Pharmaceutical
DE69839355T2 (de)	1997-07-29	2009-06-04	Alcon Laboratories, Inc., Fort Worth	Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
WO1999038504A1 (en)	1998-01-29	1999-08-05	Sepracor Inc.	Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en)	1999-09-16	2014-11-18	Ocularis Pharma, Llc	Ophthalmic formulations including selective alpha 1 antagonists
US6831186B2 (en) *	2001-11-06	2004-12-14	Schering Aktiengesellschft	Lipoxin A4 analogs
EP1453819A2 (en)	2001-12-03	2004-09-08	Novozymes A/S	Statin-like compounds
US7582785B2 (en) *	2002-04-01	2009-09-01	University Of Southern California	Trihydroxy polyunsaturated eicosanoid derivatives
US6933289B2 (en)	2003-07-01	2005-08-23	Allergan, Inc.	Inhibition of irritating side effects associated with use of a topical ophthalmic medication
DK1654002T4 (da)	2003-08-07	2014-02-17	Allergan Inc	Sammensætninger til fremføring af terapeutiske midler til øjnene
US20050059744A1 (en)	2003-09-12	2005-03-17	Allergan, Inc.	Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2699483A1 (en) *	2007-09-14	2009-03-26	Resolvyx Pharmaceuticals, Inc.	Compositions and methods for modulating immune function
EP2214660A2 (en) *	2007-10-12	2010-08-11	Resolvyx Pharmaceuticals, Inc.	Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions
DE102008027146B4 (de)	2008-06-02	2012-01-19	Ing. Erich Pfeiffer Gmbh	Austragvorrichtung
US8619544B2 (en)	2008-09-23	2013-12-31	Qualcomm Incorporated	Apparatus and method for facilitating transmit diversity for communications
WO2010039531A1 (en) *	2008-09-23	2010-04-08	Resolvyx Pharmaceuticals, Inc.	Therapeutic compounds

2010
- 2010-03-30 TW TW099109567A patent/TW201039815A/zh unknown
- 2010-04-13 EP EP10764985.7A patent/EP2419399B1/en not_active Not-in-force
- 2010-04-13 MX MX2011010827A patent/MX2011010827A/es active IP Right Grant
- 2010-04-13 BR BRPI1011325A patent/BRPI1011325A2/pt not_active IP Right Cessation
- 2010-04-13 RU RU2011146005/04A patent/RU2543720C2/ru not_active IP Right Cessation
- 2010-04-13 CA CA2758586A patent/CA2758586A1/en not_active Abandoned
- 2010-04-13 JP JP2012506110A patent/JP5785537B2/ja not_active Expired - Fee Related
- 2010-04-13 AU AU2010236663A patent/AU2010236663B2/en not_active Ceased
- 2010-04-13 ES ES10764985.7T patent/ES2576086T3/es active Active
- 2010-04-13 WO PCT/US2010/030813 patent/WO2010120719A1/en not_active Ceased
- 2010-04-13 US US13/264,155 patent/US8673881B2/en not_active Expired - Fee Related
- 2010-04-13 CN CN201080026180.0A patent/CN104203901A/zh active Pending
- 2010-04-13 NZ NZ596228A patent/NZ596228A/en not_active IP Right Cessation
2011
- 2011-10-06 IL IL215592A patent/IL215592A/en not_active IP Right Cessation
- 2011-10-13 CL CL2011002548A patent/CL2011002548A1/es unknown
2014
- 2014-03-12 US US14/207,342 patent/US9315447B2/en active Active

Also Published As

Publication number	Publication date
CN104203901A (zh)	2014-12-10
US20140275247A1 (en)	2014-09-18
TW201039815A (en)	2010-11-16
NZ596228A (en)	2014-01-31
JP5785537B2 (ja)	2015-09-30
RU2011146005A (ru)	2013-05-20
AU2010236663B2 (en)	2015-08-20
US9315447B2 (en)	2016-04-19
RU2543720C2 (ru)	2015-03-10
JP2012523459A (ja)	2012-10-04
US20120101061A1 (en)	2012-04-26
IL215592A0 (en)	2011-12-29
WO2010120719A1 (en)	2010-10-21
IL215592A (en)	2017-02-28
MX2011010827A (es)	2012-01-20
CL2011002548A1 (es)	2012-07-20
US8673881B2 (en)	2014-03-18
EP2419399A4 (en)	2012-08-29
ES2576086T3 (es)	2016-07-05
CA2758586A1 (en)	2010-10-21
EP2419399B1 (en)	2016-03-23
EP2419399A1 (en)	2012-02-22
HK1166305A1 (zh)	2012-10-26
AU2010236663A1 (en)	2011-11-24

Publication	Publication Date	Title
BRPI1011325A2 (pt)	2016-03-15	composições e métodos para o tratamento de inflamação
BR112012004979A2 (pt)	2015-09-08	composições para o tratamento de semente e métodos
BRPI1007972A2 (pt)	2016-09-13	composições de combinação e métodos para o tratamento de câncer
BRPI0919238A2 (pt)	2019-09-24	métodos e composições para o tratamento de câncer
BR112013019732A2 (pt)	2016-10-25	composições e métodos para tratamento de doenças cardiovasculares
BRPI0908854A2 (pt)	2019-09-24	composições e métodos para o tratamento de tumor de origem hematopoética
BRPI0909164A2 (pt)	2016-06-21	método e composições para o tratamento de câncer
BRPI1012525A2 (pt)	2018-07-10	composições de nanopatículas isentas de príons e métodos para sua fabricação
BR112012028514A2 (pt)	2017-11-21	composição para o tratamento da água residual e processo para o tratamento de água residual
BRPI0910259A2 (pt)	2015-12-01	métodos de tratamento de inflamação
BRPI1008566A2 (pt)	2017-06-06	métodos e composições para o diagnóstico e tratamento de câncer
BRPI1007600A2 (pt)	2019-09-24	composições e métodos para tratamento de doenças cardiovasculares
PT2434891T (pt)	2020-10-23	Métodos para tratamento de cancro e afeções não neoplásicas
BR112012031446A2 (pt)	2019-09-24	componentes e métodos para implantes
BRPI1008326A2 (pt)	2015-08-25	Composições e métodos para controlar nanatódeos
PT2512502T (pt)	2018-05-02	Métodos e composições para supressão de tumores
EP2331564A4 (en)	2013-02-20	PROCESS FOR TREATMENT OF IGNITION
BRPI0921959A2 (pt)	2017-05-30	métodos e composições para remoção de tatuagem
BRPI1008564A2 (pt)	2018-02-27	métodos e composições para o dignóstico e tratamento de câncer
FI20096058A0 (fi)	2009-10-13	Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
PT2632452T (pt)	2019-01-10	Compostos e composições para o tratamento do cancro
BRPI1013927A2 (pt)	2016-04-05	métodos e composições para o tratamento de lúpus
BRPI1007929A2 (pt)	2015-09-01	"métodos e composições para o tratamento de neovascularização".
BRPI1014528A2 (pt)	2016-04-05	compostos para tratamento de inflamação e dor
BR112012004080A2 (pt)	2016-03-08	composições farmacêuticas para tratar ibd

Legal Events

Date	Code	Title
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-02-06	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-05-22	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]